For example, the mouse colon tumor model CT26 has the highest immunogenicity and is the most responsive model to CTLA4 treatment among the models tested while the melanoma model B16F10 had the lowest immunogenicity and no response to the checkpoint inhibitors tested in our study, in contrast to the relatively high level of immunogenicity and response to checkpoint inhibitors for human melanomas. Here, CTLA4 is linked to colonic neoplasm.